Semaglutide and Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, GLP-1R has not yet been identified on human myocardial cells, negating any direct effects of GLP-1RAs on myocardial cells.470”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [470]
In the citing paper
“In this trial, semaglutide benefited patients with heart failure and preserved ejection fraction by intervening with upstream metabolic drivers.”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [470]
In the citing paper
“These positive results indicate that the change in myocardial cells may not be the primary driver of HFpEF; instead, the multisystem pathologic processes that are associated with this condition have long been well established as drivers of its clinical presentation and outcomes.470”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [470]
In the citing paper
“The results of a trial of semaglutide in obese patients with HFpEF showed a significant amelioration of symptoms and improvements in motor function and weight loss compared with patients treated with a placebo.470”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [470]
In the citing paper
“One could argue that the success of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and now of GLP-1RAs, suggests that metabolic abnormalities play an important role in driving HFpEF.470”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [470]
Citations
Cites
Pieske, B., Tschöpe, C., de Boer, R. A., Fraser, A. G., Anker, S. D., Donal, E., Edelmann, F., Fu, M., Guazzi, M., Lam, C. S. P., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz641 · Cited by 1,855
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Assessment of blinding in clinical trials
Bang, H., Ni, L., & Davis, C. E. (2004) · Controlled Clinical Trials · doi:10.1016/j.cct.2003.10.016 · Cited by 682
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care
Spertus, J. A., Jones, P. G., Sandhu, A. T., & Arnold, S. V. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.542 · Cited by 619
Lovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Prevention of Pathological Atrial Remodeling and Atrial Fibrillation
Chen, Y. C., Voskoboinik, A., Gerche, A. L., Marwick, T. H., & McMullen, J. R. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.012 · Cited by 159
Yap, J. J. L., Lim, F. Y., Gao, F., Teo, L. L., Lam, C. S. P., & Yeo, K. K. (2015) · Clinical Cardiology · doi:10.1002/clc.22468 · Cited by 146
Skov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.05.010 · Cited by 97
Smits, M. M., ten Kulve, J. S., van Bloemendaal, L., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., IJzerman, R. G., & van Raalte, D. H. (2019) · Nutrition · doi:10.1016/j.nut.2019.06.005 · Cited by 5
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00469-0 · Cited by 386
Deanfield, J., Lincoff, A. M., Kahn, S. E., Emerson, S. S., Lingvay, I., Scirica, B. M., Plutzky, J., Kushner, R. F., Colhoun, H. M., Hovingh, G. K., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01375-3 · Cited by 143
Ma, Y., Kong, C., Guo, Z., Wang, M., Wang, P., Liu, F., Yang, D., Zheng, Y., & Tang, Q. (2024) · Nature Communications · doi:10.1038/s41467-024-48970-2 · Cited by 110
“Semaglutide (Sema), in contrast, has exhibited cardiovascular advantages in clinical trials, notably among HF patients with obesity and preserved ejection fraction 14 .”
2026 iCARDIO Alliance Global Implementation Guidelines on Heart Failure
Chopra, V., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D., Burgos, L. M., Butler, J., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.70 · Cited by 23
Metadata
- Authors
- Gao, Y., Gao, Y., & Qiu, H.
- Affiliations
- Qingdao University (CN)
- Beijing YouAn Hospital (CN)
- Beijing Friendship Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-21
- Volume
- 389
- Issue
- 25
- Pages
- 2397-2399
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4390034482
- Cited by
- 26
- References
- 10
- Citations by year
- 2026: 6 · 2025: 13 · 2024: 7
- Type
- journal article
- Language
- en
- Open access
- green
- eprints.gla.ac.uk
- Licence
- cc-by-sa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, GLP-1 receptor agonists, obesity cardiomyopathy, heart failure treatment
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.